Alteration in RNA splicing is implicated in carcinogenesis and progression. Mutations in spliceosome genes and alternative splicing of other genes have been noted in chronic lymphocytic leukaemia (CLL), a common B cell malignancy with heterogeneous outcomes. We previously demonstrated that differences in the amount of SET oncoprotein (a physiological inhibitor of the serine/threonine phosphatase, PP2A) is associated with clinical aggressiveness in patients with CLL. It is unknown if alternative splicing of gene transcripts regulating kinases and phosphatases affects disease pathobiology and CLL progression. We show here for the first time that mRNA levels of the alternatively spliced SET isoforms, SETA and SETB (SETa and SETb), significantly correlate with disease severity (overall survival and time-to-first-treatment) in CLL patients. In addition, we demonstrate that relative increase of SETA to SETB mRNA can discriminate patients with a more aggressive disease course within the otherwise favourable CLL risk classifications of IGHV mutated and favourable hierarchical fluorescence in situ hybridisation groups. We validate our finding by showing comparable relationships of SET mRNA with disease outcomes using samples from an independent CLL cohort from a separate institution. These findings indicate that alternative splicing of SET, and potentially other signalling cascade molecules, influences CLL biology and patient outcomes.
Summary
Alteration in RNA splicing is implicated in carcinogenesis and progression. Mutations in spliceosome genes and alternative splicing of other genes have been noted in chronic lymphocytic leukaemia (CLL), a common B cell malignancy with heterogeneous outcomes. We previously demonstrated that differences in the amount of SET oncoprotein (a physiological inhibitor of the serine/threonine phosphatase, PP2A) is associated with clinical aggressiveness in patients with CLL. It is unknown if alternative splicing of gene transcripts regulating kinases and phosphatases affects disease pathobiology and CLL progression. We show here for the first time that mRNA levels of the alternatively spliced SET isoforms, SETA and SETB (SETa and SETb), significantly correlate with disease severity (overall survival and time-to-first-treatment) in CLL patients. In addition, we demonstrate that relative increase of SETA to SETB mRNA can discriminate patients with a more aggressive disease course within the otherwise favourable CLL risk classifications of IGHV mutated and favourable hierarchical fluorescence in situ hybridisation groups. We validate our finding by showing comparable relationships of SET mRNA with disease outcomes using samples from an independent CLL cohort from a separate institution. These findings indicate that alternative splicing of SET, and potentially other signalling cascade molecules, influences CLL biology and patient outcomes.
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Chronic lymphocytic leukaemia (CLL) is characterized by marked clinical heterogeneity whereby some patients never require treatment and have life expectancies similar to their age-matched peers, while other patients experience rapid progression and treatment resistance with significantly shortened survival (Chiorazzi et al, 2005 , Pflug et al, 2014 Parikh et al, 2016 ; The International CLL-IPI Working Group 2016; Thompson et al, 2016) . Despite significant advances in CLL, including available novel therapeutics, there remains great variability in outcomes; a better understanding of disease pathobiology is needed to identify these disparate groups.
Alternative RNA splicing can alter normal cellular functions, cooperating with other oncogenic progresses to drive leukaemogenesis or cancer progression (Hanahan & Weinberg, 2011; Surget et al, 2013) . In both adult and paediatric AML, for instance, relative change in the expression of the different alternatively spliced isoforms of BIRC5 (survivin), an inhibitor of apoptosis protein, is related to risk of aggressive disease relapse and rapid progression with shortened patient survivals (Beghini et al, 2000; Wagner et al, 2006; Moore et al, 2014) . In lymphoid malignancies, such as CLL, mutations in certain spliceosome-related genes and alternative splicing also appear to modulate disease severity. For example, in CLL, mutations in the 3 0 region of NOTCH1 induce aberrant NOTCH1 mRNA splice variants (Puente et al, 2015) and SF3B1 mutations induce alternative splicing in numerous genes (Wang et al, 2017) . Both NOTCH1 and SF3B1 mutations are associated with inferior CLL-specific clinical outcomes. Recent advances in the understanding of the critical role that B-cell receptor signalling and modulation of apoptosis play in CLL has led to development and use of novel therapies in this malignancy (Byrd et al, 2013; Furman et al, 2014) . SET protein, a potent endogenous inhibitor of protein phosphatase 2A (PP2A), is a known regulator of oncogenic signalling, apoptosis and the cell cycle. For this reason, we previously evaluated SET protein in CLL, and demonstrated that the SETa and SETb proteins are expressed at higher levels in malignant CLL and non-Hodgkin lymphoma (NHL) cells compared to normal B cells .
Because of the growing appreciation of RNA splicing as an oncogenic mechanism, we here measured SETA and SETB mRNA expression in CLL cells from patients attending the Duke University or Durham Veteran's Affairs Medical Centers (Duke/DurVAMC), and from patients in an independent cohort of CLL patients from the Moores Cancer Center of the University of California San Diego (UCSD). Additionally, we evaluated the extent to which relative expression of SET isoforms influences disease progression within the context of established clinical and molecular prognostic factors. This evaluation connects the oncogenic processes of alternative splicing and second messenger signalling on the cellular level with the heterogeneity of disease aggressiveness that can be observed in patients with CLL.
Methods

Patient inclusion & CLL cell preparation
Patients diagnosed with CLL at Duke/DurVAMC and the UCSD, were enrolled on Institutional Review Boardapproved protocols to collect clinical data and peripheral blood. All patients provided written, informed consent prior to enrolment in accordance with the Declaration of Helsinki. Indications for treatment were based on the International Workshop on CLL guidelines (Hallek et al, 2008) , but selection and timing of therapy was at the discretion of the treating physicians. Some patients had treatment prior to being evaluated at the participating centres. Time to first treatment (TTFT) was defined as the length of time from the date of CLL diagnosis to initiation of first treatment. Overall survival (OS) was defined as the length of time from diagnosis to death from any cause. The follow-up time was the time from initial diagnosis until the time of death or the time of last contact.
CLL cells from the first collected sample were purified as previously published. In brief, Duke/DurVAMC CLL cells were enriched using the RosetteSepâ B cell enrichment cocktail (Stem Cell Technologies, Vancouver, BC, Canada) according to the manufacturer's directions, yielding a CLL purity by flow cytometry (CD5 + CD19 + B-cells) of greater than 95% . At UCSD, the leukaemia cells were isolated by ficoll/Hypaque density gradient technique (Rassenti et al, 2004) . Patient characteristics and prognostic markers were obtained from clinical records, with the IGHV mutation status and CD38 expression levels determined on the Duke/DurVAMC samples as previously described . In every case, the first sample available was utilized to calculate CD38 expression levels and determine positivity (≥30% considered positive).
Quantitative polymerase chain reaction measurement of SET mRNA
Primers and probes for quantitative real time polymerase chain reaction (RT-qPCR) designed to amplify only the alpha or beta forms of SET are described in Fig 1 and SETA, SETB and total primers and probes. The SETA forward primer is located within exon 1, which is unique to the alpha form. The SETB forward primer is located within exon 2, which is unique to the beta form. The reverse primer for both SETA and SETB lies within exon 3, which is common to both forms of SET. The SETA probe lies partially in the alpha exon and partially in the common exon. The SETB probe lies entirely in the beta exon. A primer/probe combination was also designed in order to amplify all SET mRNA isoforms. The forward primer, the reverse prime, and the probe all lie in the common exon. All primers and probes were purchased from Integrated DNA Technologies (Coralville, Iowa). SETA forward primer: AGAAGAAACCAAGACCACCTCCTG Reverse primer for both SETA and SETB: GTGTTCAATCGCTT CTTGCTGTTC SETA probe: TGCAGGCTTGCCGAAGAAGGGAGAAA SETB probe: AAGGAGCTCAACTCCAACCACGACG Forward primer for all SET isoforms: CCA TCT TCG AAG TCC ACC GAA ATC Reverse primer for all SET isoforms: GCC TCT TCC TGC TGG CTT TAT T Probe for all SET isoforms: GGA TTT GAC GAA ACG TTC GAG TCA AAC GCA.
Statistical analyses
For the primary inferential analysis of TTFT and OS, the SETA/SETB mRNA ratio was analysed as a continuous variable. The dichotomized data were used for visual display of the effects in Kaplan-Meier plots (high versus low SETA/SETB mRNA ratio); an individual patient's CLL cell SETA/SETB mRNA ratio at or above the median ratio for the group was considered a "high SET ratio;" if the SETA/SETB was below the median ratio it was considered a "low SET ratio." The secondary analysis was to test for an interaction effect of SETA/SETB ratio with other established CLL risk biomarkers. The primary inferential analyses were based on the continuous variables, and the dichotomized data were used for visual display of the effects in Kaplan-Meier plots. The secondary analysis was to test for an interaction effect of SETA/ SETB mRNAratio with other established CLL risk biomarkers including Rai stage, IGHV mutation status, CD38 positivity (≥30% considered positive) and favourable versus unfavourable A (unfavourable = del(17p) or del(11q) alone or in any combination, or three or more abnormalities) with respect to TTFT and OS. This interaction testing was to determine if the effect of the effect of the SETA/SETB mRNA on patient outcomes was dependent on the other prognostic variables (positive interaction).
The distributions of continuous variables were assessed using boxplot, and log2 transformation was used for skewed variables. All statistical analyses were conducted using the R statistical environment v3.3.2 (https://www.r-project.org/). Cox proportional hazard regression was used for the time to event analyses using the R extension package survival v2.40. (Cox & Oakes, 1984; Therneau, 2016) Score test P-values 
Results
Patient characteristics
The Duke/DurVAMC combined population was analysed independently from the validation cohort of UCSD patients.
The median SETA/SETB mRNA ratio (SETA/B) of the Duke/ DurVAMC population was 0Á94 (range = 0Á13-33Á50) and the median for the UCSD population was 0Á93 (range = 0Á24-19Á20) (P = not significant). Patient characteristics of the analysed Duke/DurVAMC (n = 307) and UCSD cohorts (n = 166) are summarized in Table I . FISH is reported hierarchically as detailed in Table I footnotes. The cohorts were representative of other published CLL populations with regards to age and distribution of prognostic factors (Molica et al, 2016) . There were no significant differences between the Duke/DurVAMC and UCSD patients relative to sex (32% vs. 40% female, respectively, P = 0Á1) and low risk Rai stage 0 at diagnosis. Patients in the San Diego cohort had higher CD38 positivity than those in the Duke/DurVAMC cohort (28% vs. 19%; P = 0.047), but the percent of patients with the adverse marker unmutated IGHV (UM-IGHV) was not significantly different between the groups (43% vs. 39%, P = 0Á529).
Increased SETA isoform mRNA relative to SETB isoform mRNA is associated with CLL aggressiveness
The median follow-up time for the Duke/DurVAMC patients was 16Á3 years. Established biomarkers and the SETA/B mRNA ratio were tested in univariate analyses for TFTT in both cohorts. As others and we have noted before, UM-IGHV, CD38 positivity (CD38 + ) and Rai stage I-IV at diagnosis were significantly associated with shorter times to first treatment in both groups (Chiorazzi et al, 2005; Weinberg et al, 2007) . In the Duke/DurVAMC cohort, patients with unfavourable FISH [del(17p), del(11q) or three or more than 3 cytogenetic abnormalities by FISH] had a significantly shorter TTFT and OS (Table II) , but those with del(17p) alone did not have a shorter TTFT. The number of patients with del(17p) was small, and this may have limited the power of this analysis. We measured SETA and SETB mRNA using isoform-specific RT-PCR, and evaluated both isoforms with respect to their influence on clinical outcomes by calculating a ratio of SETA to SETB. Patients with higher SETA/B mRNA ratio assessed as a continuous variable had significantly shorter TTFT, [hazard ratio (HR) 1Á2, P = 0Á001]. Results of analyses of the SETA/B mRNA ratio as a dichotomous variable in TTFT and OS (for illustrative purposes only) is displayed as Kaplan-Meier plots in Fig 2 and included in Table II. Patients with a dichotomized high SETA/B mRNA ratio had a median TTFT of 4Á3 years (3Á5-5Á5), while patients with a low SETA/B mRNA ratio had a median TTFT of 9Á3 years As some CLL biomarkers can evolve and be enriched postchemoimmunotherapeutic treatment, we additionally analysed the patients from the Duke cohort who had a sample for SET mRNA PCR analysis collected prior to any therapeutic intervention. In all cases, we utilized the first sample that was available. In the Duke cohort, 233 patients had TTFT (or follow-up with no treatment) information available and had a CLL sample for qPCR analysis of SET mRNA isoforms collected prior to the first treatment. Of these 233 patients, 116 eventually were treated. As a continuous variable, the HR for TTFT for a higher SET mRNA ratio in this group was 1Á05 [95% CI (1Á01-1Á09)], P = 0Á01. Similarly, 234 patients in the Duke cohort had OS data available and had their CLL sample for analysis drawn before any therapy was given. Sixty-two of these patients later died. The HR for a higher SET mRNA ratio and death in these patients was 1Á06 (1Á02-1Á11), P = 0Á004. Therefore SET mRNA isoform ratio retains its prognostic significance for TTFT and OS even when tested in patients of the Duke cohort who had their samples taken before any chemoimmunotherapy was given. 
CI, confidence interval; CLL, chronic lymphocytic leukaemia; FISH, fluorescence in situ hybridisation; UCSD, University of California San Diego.
SET mRNA and CLL Analysis of the interaction of SETA/SETB mRNA ratio with IGHV mutation status and FISH group for the Duke/DurVAMC cohort for TTFT and OS. The figure shows the interaction of SETA/B mRNA ratio as a dichotomous variable with IGHV mutation status (top) and FISH (bottom) for TTFT (left) and OS (right). As expected, for unfavourable risk UM-IGHV patients (blue and yellow lines), there was shorter TTFT compared to M-IGHV (red and green lines), and for UM-IGHV this poor prognosis appeared independent of the SETA/B mRNA ratio. However, within the favourable risk M-IGHV patients, those with high SETA/B mRNA ratio (red) had a shorter TTFT compared to low SETA/B mRNA ratio (green). This interaction between IGHV mutation status and SETA/B mRNA ratio in TTFT is significant (P = 0Á01). As expected for patients with unfavourable FISH, defined as any del(17p), del (11q) or three or more abnormalities by FISH (red and green lines), there was shorter TTFT compared to favourable FISH (blue and yellow lines), and for UM-IGHV this poor prognosis appeared independent of the SETA/B mRNA ratio. However, within the favourable FISH population, those with high SETA/ B mRNA ratio (blue) had a shorter TTFT compared to low SETA/B mRNA ratio (yellow). This interaction between FISH group and SETA/B mRNA ratio in TTFT was significant (P = 0Á01). Duke/DurVAMC, Duke University or Durham Veteran's Affairs Medical Centers; FISH, fluorescence in situ hybridisation; M-IGHV, mutated IGHV; OS, overall survival; TTFT, time to first treatment; UM-IGHV, unmutated IGHV.
SETA/B mRNA ratio [HR 1Á8 (1Á2-2Á7), P = 0Á006]. There was no significant association of high SETA/B mRNA ratio as a continuous or dichotomous variable with shortened OS in the UCSD patients. The lower number of deaths in the UCSD cohort may have contributed to the difference in effect on OS seen between the two cohorts.
Increased SETA isoform mRNA relative to SETB isoform mRNA provides risk stratification in favourable CLL prognostic groups
Clinically established prognostic markers, such as Rai stage, CD38 positivity, IGHV mutation status and FISH profile, do not fully predict CLL patient outcomes. This indicates that additional modifiers of disease aggressiveness probably exist. We therefore first tested for interactions of the dichotomous SETA/B mRNA ratio with IGHV mutation status, FISH group, CD38 positivity and Rai staging in the Duke/Dur-VAMC cohort. As expected, CLL patients with UM-IGHV have a shorter TTFT compared to patients with mutated IGHV (M-IGHV) [3Á1 years vs. 11Á9 years, HR = 3Á34, P < 0Á001; Fig 3] . Patients with M-IGHV and a high SETA/B mRNA ratio had a shorter TTFT compared to those with M-IGHV and a low SETA/B mRNA ratio. However, SETA/B mRNA ratio did not risk stratify the unfavourable risk UM-IGHV group of patients (P interaction = 0Á01). As with the UM-IGHV patients, CLL patients with unfavourable FISH had a shorter TTFT compared to those with favourable FISH [4Á6 years vs. 7Á3 years, HR = 1Á6, P < 0Á001]. In the favourable risk FISH group, a high SETA/ B mRNA ratio predicted a shorter TTFT compared to low SETA/B mRNA ratio, but this risk stratification was not seen in the unfavourable FISH group (P interaction = 0Á01). SETA/B mRNA ratio appeared to risk-stratify CLL patients when combined with other established prognostic markers in the Duke/DurVAMC cohort (Rai stage and CD38 -Fig 4) and the UCSD cohort (IGHV mutation status or the FISH group - Fig 5) , although there were no significant interactions in these analyses. Interaction of SET isoform mRNA ratio with CD38 may part be partly affected by the known variability of CD38 in patients across time, while IGHV and FISH have more consistently been shown to be independent prognostic markers, including in a validated international prognostic index, the CLL-IPI (The International CLL-IPI Working Group, 2016) .
The positive interactions of IGHV and FISH with SET mRNA isoforms indicates that a high SETA/B mRNA ratio is associated with inferior clinical outcomes and can be combined with established prognostic markers for more refined estimation of patient prognosis. The interaction between SETA/B Fig 5. Analysis of the interaction of SETA/B mRNA ratio with IGHV mutation status and FISH group for the UCSD cohort for TTFT and OS. The figure shows the interaction of SETA/B mRNA ratio as a dichotomous variable with IGHV mutation status (top) and FISH (bottom) for TTFT (left) and OS (right). There is no evidence for significant interaction between SET mRNA ratio and either IGHV mutation status or FISH group. FISH, fluorescence in situ hybridisation; M-IGHV, mutated IGHV; OS, overall survival; TTFT, time to first treatment; UCSD, University of California San Diego; UM-IGHV, unmutated IGHV.
mRNA ratio and IGHV mutation status or FISH group suggests that SET may cooperate with other proteins or cellular pathways in certain biologically-defined patient subgroups, thereby influencing disease aggressiveness primarily for those patients.
Discussion
We present here that expression of the alternatively spliced SET mRNA isoforms is associated with clinical outcomes in patients with CLL. We show for the first time that a relative increase in the expression of SETA mRNA isoform (high SETA/B mRNA ratio) is associated with shortened TTFT and OS in CLL patients. Using an independent group of CLL patients from a separate institution, we also verified that patients with high SETA relative to SETB isoform mRNA expression have inferior outcomes with faster progression to treatment indications (Fig 2) . We believe this provides novel insights into CLL disease biology, potentially through SET's role in dysregulation of the critical kinase-phosphatase balance. However, the dominant function(s) of each SET isoform and the comparative potency between isoforms for these various SET functions in malignant cells is not defined. Alternative splicing of SET mRNA isoforms may provide an additional layer of oncogenic dysregulation in CLL.
SET overexpression and involvement in tumourigenesis has been described in many cancers, including lung, prostate, ovarian and head and neck cancers, and leukaemias (Carlson et al, 1998; Neviani et al, 2005; Christensen et al, 2011; Switzer et al, 2011; Cristobal et al, 2012 Cristobal et al, , 2015 Cristobal et al, , 2017 Agarwal et al, 2014; Gonzalez-Alonso et al, 2015; Liu et al, 2015) . SET is the primary and most potent physiological inhibitor of PP2A, (Switzer et al, 2011; Neviani & Perrotti, 2014 ) a major mammalian serine/threonine phosphatase that plays a critical regulatory role in the cell cycle, apoptosis and appropriate deactivation of oncogenic signalling. Decreased activity of PP2A in CLL due to inappropriate SET protein isoform balance may lead to unregulated kinase activity and unchecked growth and replication, thereby permitting progression of the CLL clone. (Ciccone et al, 2015) .
It is now recognized that there are at least four SET isoforms formed from alternative splicing, with SETA (SET-204) and SETB (SET-201) considered the main protein isoforms (Adachi et al, 1994) . To date, investigators have generally focused on the role of total SET in human malignancies without elucidating the impact of relative differences in splice variant expression in disease heterogeneity. Our findings raise questions regarding the shared and independent roles that that the two main splice variants of SET (SETA and SETB) have in oncogenesis and cancer progression, as well as questions regarding the mechanisms that control isoform-specific SET expression in CLL. While normal B cells predominantly contained the b isoform of SET protein, we noted in our prior work that both SETA and B protein were expressed in CLL and NHL cells . SETA and SETB are both capable of inhibiting PP2A (Saito et al, 1999) activity and inhibiting nucleosome acetylation (Saavedra et al, 2017) . We are not aware of research identifying the independent functions of the two SET isoforms or the mechanisms that regulate different SET isoform expression in CLL. The relative differences in SETA and SETB mRNA expression between CLL patients found in this study highlight the need for ongoing work to elucidate the roles of the different SET isoforms and the factors that control their differential expression.
In our cohorts, we found that increased SETA isoform mRNA relative to SETB isoform mRNA identifies a high-risk group within the mutated IGHV and favourable FISH risk groups (Fig 2) . We hypothesize that SET may impact the Bcell receptor (BCR)-mediated kinase pathway signalling, which can be affected by IGHV mutation status (Kipps et al, 2017) . In UM-IGHV, BCR activation can enhance pathways associated with proliferation and cellular survival (Packham et al, 2014) , and this heightened kinase signalling may be too strong to be negatively regulated by the SET-PP2A axis. Therefore, any relative differences between patients in SET inhibition of PP2A (as reflected in the SETA/B mRNA ratio) may not have a large impact in patients with UM-IGHV. Conversely, in M-IGHV CLL, BCR signalling may activate proliferation pathways to a lesser degree, and this diminished kinase signalling response may be more likely to be modulated by the SET-PP2A axis. Thus, relative changes in SET protein isoforms and subsequent relative changes in PP2A activity could lead to different outcomes based on IGHV mutation status.
In summary, we have found that patients with CLL containing relatively higher expression of SETA isoform mRNA (high SETA/B mRNA ratio) have significantly shorter TTFT and OS compared to those with lower levels, and that this ratio identifies patients with worse clinical outcomes within previously defined CLL favourable risk groups. These results highlight that alternative splicing of SET mRNA may be an important oncogenic control mechanism. Additional work is needed to understand the functional differences in SETA and SETB protein isoforms. CLL patients will benefit from a deeper understanding of the function and control of SET mRNA isoforms and of alternative splicing in general, in that this knowledge can lead to improved patient counseling and development of novel therapeutics in CLL that modulate epigenetics and/or phosphatase activity. 
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